Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL-Reference-Cited by-同舟云学术

Impact of dual expression of MYC and BCL2 by immunohistochemistry on the risk of CNS relapse in DLBCL

Published:2016-05-05 Issue:18 Volume:127 Page:2182-2188
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Savage Kerry J.¹^ORCID,Slack Graham W.²,Mottok Anja²,Sehn Laurie H.¹,Villa Diego¹,Kansara Roopesh³,Kridel Robert²,Steidl Christian²,Ennishi Daisuke²,Tan King L.²,Ben-Neriah Susana²,Johnson Nathalie A.⁴,Connors Joseph M.¹,Farinha Pedro²,Scott David W.¹,Gascoyne Randy D.²

Affiliation:

1. Department of Medical Oncology and

2. Department of Pathology and Laboratory Medicine, Centre for Lymphoid Cancer, British Columbia Cancer Agency, Vancouver, BC, Canada;

3. Section of Medical Oncology/Hematology, Cancer Care Manitoba, Winnipeg, MB, Canada; and

4. Division of Hematology, Sir Mortimer B. Davids-Jewish General Hospital, Montreal, QC, Canada

Abstract

Key Points Dual expression of MYC and BCL2 is associated with an increased risk of CNS relapse in DLBCL treated with R-CHOP.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/127/18/2182/1392904/2182.pdf

Reference38 articles.

1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.;Coiffier;N Engl J Med,2002

2. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.;Pfreundschuh;Lancet Oncol,2011

3. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma.;Habermann;J Clin Oncol,2006

4. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia.;Sehn;J Clin Oncol,2005

5. Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL).;Boehme;Ann Oncol,2007

Cited by 152 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Central nervous system prophylaxis in large B‐cell lymphoma: A British Society for Haematology Good Practice Paper;British Journal of Haematology;2024-08-11

2. Clinicopathological differences in MYC and BCL2 protein expression between primary extranodal and nodal diffuse large B-cell lymphoma;Pathology - Research and Practice;2024-08

3. Analysis of Diffuse Large B Cell Lymphoma using Immunohistochemistry to Identify Double Expressor Diffuse Large B Cell Lymphoma among Germinal Centre and Non Germinal Centre B Cell Subtypes;Medical Journal of Dr. D.Y. Patil Vidyapeeth;2024-07

4. Polatuzumab vedotin in diffuse large B-cell lymphoma therapy: Literature review and experience of the Oncohematology Division of the Lapino Clinical Hospital;MD-Onco;2024-06-14

5. Sinonasal DLBCL: molecular profiling identifies subtypes with distinctive prognosis and targetable genetic features;Blood Advances;2024-04-12